Clinical Trials Directory

Trials / Withdrawn

WithdrawnNCT03016104

Magnetic Seizure Therapy vs. Electroconvulsive Therapy for Bipolar Mania

Status
Withdrawn
Phase
N/A
Study type
Interventional
Enrollment
0 (actual)
Sponsor
Shanghai Mental Health Center · Academic / Other
Sex
All
Age
18 Years – 55 Years
Healthy volunteers
Not accepted

Summary

This trial attempts to evaluate the treatment efficacy of magnetic seizure therapy (MST) and its safety for bipolar mania. Half of the participants will receive MST, while the other half will receive electroconvulsive therapy (ECT).

Detailed description

Magnetic seizure therapy (MST) is likely to be an alternative options to electroconvulsive therapy (ECT). Widespread stimulation of cortical and subcortical regions is inevitable for ECT since the substantial impedance of the scalp and skull shuts most of the electrical stimulus away from the brain. Nevertheless, magnetic pulses are capable to focus the stimulus to a specific area of the brain because they can pass the scalp and skull without resistance. In Addition, electric current will penetrate into deeper structures, while magnetic stimulus are only capable to reach a depth of a few centimeters. As a consequence, MST are able to generate focus stimuli on superficial regions of the cortex while ECT can't, which may give MST the capability to produce comparable therapeutic benefits with the absence of apparent cognitive side effects.

Conditions

Interventions

TypeNameDescription
DEVICEMagpro X100 + OptionIn addition to treatment as usual (TAU), participants were supposed to receive ten sessions of MST in four weeks, with three sessions per week in the first two weeks and two sessions per week in the following two weeks.
DEVICEThymatronSystem Ⅳ Electroconvulsive SystemIn addition to treatment as usual (TAU), participants were supposed to receive ten sessions of modified ECT in four weeks, with three sessions per week in the first two weeks and two sessions per week in the following two weeks
OTHERtreatment as usual (TAU)Participants will engage in their inpatient treatment program as-usual.

Timeline

Start date
2016-11-01
Primary completion
2017-10-01
Completion
2017-12-01
First posted
2017-01-10
Last updated
2022-05-11

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT03016104. Inclusion in this directory is not an endorsement.